Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:

NCT ID: NCT05532982 Recruiting - Parkinson's Disease Clinical Trials

Parkinson's Disease in Asian Americans

Start date: October 15, 2022
Phase:
Study type: Observational

The ultimate goal of this project is to use the findings to develop culturally appropriate programs and resources that can be disseminated to key stakeholders to improve access to PD care and increase inclusivity in PD research for Asian Americans. This study will serve as a first step towards developing broader community and patient education programs and active outreach campaigns to increase PD-specific literacy among Asian Americans. The results from this study will elucidate the role that language barriers, cultural perceptions, family influence, and other predisposing, enabling, or need factors have on delaying care for PD among Asian Americans. It will also provide much needed insight on how to improve inclusion of Asian Americans in PD research studies.

NCT ID: NCT05523570 Recruiting - Parkinson's Disease Clinical Trials

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Start date: August 22, 2022
Phase: Phase 1
Study type: Interventional

This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.

NCT ID: NCT05516732 Recruiting - Parkinson Disease Clinical Trials

Serotonin Release in Premotor and Motor PD

FOX3
Start date: July 1, 2022
Phase:
Study type: Observational

In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms

NCT ID: NCT05516719 Recruiting - Parkinson Disease Clinical Trials

Longitudinal Investigation of I2BS in PD

FOX_2
Start date: November 1, 2021
Phase:
Study type: Observational

In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The PET and SPECT scans use small amounts of radiation and specific compounds called tracers, to study chemical changes in the brain in a way not possible with any other procedure. The MRI uses magnetic fields to generate images of brain structure and function

NCT ID: NCT05489653 Terminated - Parkinson's Disease Clinical Trials

Mixed Music Intervention on Sleep Disturbance in Patients With Parkinson's Disease

Start date: November 10, 2022
Phase: N/A
Study type: Interventional

Parkinson's disease is a disease that is prevalent in the elderly, and the risk increases with age. Sleep disturbance is a common complaint of patients with Parkinson's disease, with a prevalence of 60% to 96%. Long-term sleep disturbance in Parkinson's disease patients significantly reduces cognitive function and quality of life. Nursing staff are the first line of care and should seek appropriate strategies to address sleep disturbances in patients with Parkinson's disease. This study is a feasibility and pilot study, which will be a single-blind, parallel randomized controlled trial. It is expected to include 30 patients with Parkinson's disease with poor sleep quality, and they will be equally allocated to the mixed music group (10 people), passive music group (10 people), and usual care group (10 people) in a 1:1:1 ratio. If assigned to the passive music group, they are required to listen to soft and low-pitched music at about 60 beats per minute for 30 minutes before sleep every day for four weeks. If assigned to the mixed music group, in order to synchronize active daytime music and passive music at bedtime, active daytime music will require patients to perform physical music activities once a week and watch a recorded music intervention video three times a week during the study period (The content is the same as the physical music activities) and follow the activities, and the intervention content before going to bed is the same as the intervention content of the pure passive music group. Subjects assigned to the usual care group maintained their original lifestyle and were assisted by study evaluators to complete pre-and post-test data. The researchers will establish a line group, and the three groups of patients or primary caregivers will be contacted by line every two days to care for the patient's condition. The variables measured included anxiety, depression, quality of life, and sleep quality, as assessed by the Hospital Anxiety and Depression Scale, Parkinson 's Disease. Questionnaire - 39, and the Pittsburgh Sleep Quality Scale . This study will use one-way ANOVA and linear mixed model for statistical analysis to test the hypothesis of this study. If the effectiveness of this intervention can be confirmed, it will be implemented in Parkinson's disease patients in the future to reduce sleep disturbances and improve patients' quality of life.

NCT ID: NCT05485428 Completed - Parkinson's Disease Clinical Trials

The HIIT-Home4Parkinson's Study

HH4P
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This project aims to investigate the practicality and utility of home-based high-intensity interval training (HIIT) by undertaking a previously developed, novel home-based HIIT intervention for people with Parkinson's (PwP).

NCT ID: NCT05483036 Recruiting - Parkinson's Disease Clinical Trials

Perception in Parkinson's Disease

Start date: September 1, 2022
Phase:
Study type: Observational

The investigators plan to examine the relation of perceptual variables-basic vision, unusual perceptual experiences(including but not limited to visual hallucinations)-to relevant functional variables such as cognition, mood, and alertness/sleepiness in an online sample of persons with Parkinson's disease (PwPD). It is hypothesized that unusual perceptual experiences will relate significantly to the selected variables. Participants do not need to experience visual hallucinations to be able to participate in this study. This is an observational study only, and not an interventional study.

NCT ID: NCT05471713 Recruiting - Parkinson's Disease Clinical Trials

MAPT Haploid H1b and the Damage of BBB in Dorsal Medulla Oblongata and Autonomic Dysfunction in PD

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

This study mainly explored the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

NCT ID: NCT05435755 Not yet recruiting - Parkinson's Disease Clinical Trials

Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

Start date: December 2, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of multiple treatments of hAESCs treatments, while exploring the effectiveness of hAESCs treatments for PD.

NCT ID: NCT05435729 Completed - Parkinson's Disease Clinical Trials

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label of single transdermal dose of DSP-9632P to evaluate the dopamine release derived from levodopa in brain, and a randomized, double-blind, placebo-controlled, 2-way crossover of multiple transdermal doses of DSP-9632P to evaluate the safety and tolerability in patients with levodopa-induced dyskinesia in Parkinson's disease.